Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

738 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Cavalieri S, Serafini MS, Carenzo A, Canevari S, Lenoci D, Pistore F, Miceli R, Vecchio S, Ferrari D, Moro C, Sponghini A, Caldara A, Rocca MC, Secondino S, Moretti G, Denaro N, Caponigro F, Vaccher E, Rinaldi G, Ferraù F, Bossi P, Licitra L, De Cecco L. Cavalieri S, et al. Among authors: ferrari d. Cells. 2022 Oct 10;11(19):3176. doi: 10.3390/cells11193176. Cells. 2022. PMID: 36231138 Free PMC article.
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy.
Pietrantonio F, Perrone F, Biondani P, Maggi C, Lampis A, Bertan C, Venturini F, Tondulli L, Ferrari D, Ricci V, Villa F, Barone G, Bianco N, Ghidini A, Bossi I, Fanetti G, Di Bartolomeo M, de Braud F. Pietrantonio F, et al. Among authors: ferrari d. Cancer Biol Ther. 2013 Dec;14(12):1098-103. doi: 10.4161/cbt.26343. Epub 2013 Sep 4. Cancer Biol Ther. 2013. PMID: 24025413 Free PMC article. Clinical Trial.
Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements.
De Sanctis V, Bossi P, Sanguineti G, Trippa F, Ferrari D, Bacigalupo A, Ripamonti CI, Buglione M, Pergolizzi S, Langendjik JA, Murphy B, Raber-Durlacher J, Russi EG, Lalla RV. De Sanctis V, et al. Among authors: ferrari d. Crit Rev Oncol Hematol. 2016 Apr;100:147-66. doi: 10.1016/j.critrevonc.2016.01.010. Epub 2016 Feb 1. Crit Rev Oncol Hematol. 2016. PMID: 26947812 Review.
Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.
Pinto C, Di Fabio F, Rosati G, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrari D, Lo Re G, Rosti G, Tralongo P, Ferrara R, Alabiso O, Chiara S, Ianniello GP, Frassoldati A, Bilancia D, Campanella GA, Signorelli C, Racca P, Benincasa E, Stroppolo ME, Di Costanzo F. Pinto C, et al. Among authors: ferrari d. Cancer Med. 2016 Nov;5(11):3272-3281. doi: 10.1002/cam4.888. Epub 2016 Oct 17. Cancer Med. 2016. PMID: 27748041 Free PMC article.
Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, Baldessari C, Alù M, Nolé F, Codecà C, Boscolo G, Piccininni M, Cavalieri S, Bossi P. Depenni R, et al. Among authors: ferrari d. Eur J Cancer. 2019 Jul;115:4-12. doi: 10.1016/j.ejca.2019.03.022. Epub 2019 May 10. Eur J Cancer. 2019. PMID: 31082692
738 results